{"id":"elacestrant","rwe":[],"_fda":{"id":"42ec5c9c-8984-4561-a4eb-c6ddc916c18a","set_id":"aa66ae5c-2bd2-4444-8178-b55651e054ef","openfda":{"nui":["N0000175582","N0000000145","N0000185503","N0000190113"],"upc":["0372187010135","0372187010234"],"unii":["FM6A2627A8"],"route":["ORAL"],"rxcui":["2628478","2628484","2628487","2628489"],"spl_id":["42ec5c9c-8984-4561-a4eb-c6ddc916c18a"],"brand_name":["ORSERDU"],"spl_set_id":["aa66ae5c-2bd2-4444-8178-b55651e054ef"],"package_ndc":["72187-0101-3","72187-0102-3"],"product_ndc":["72187-0101","72187-0102"],"generic_name":["ELACESTRANT"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ELACESTRANT"],"pharm_class_epc":["Estrogen Receptor Antagonist [EPC]"],"pharm_class_moa":["Estrogen Receptor Antagonists [MoA]","P-Glycoprotein Inhibitors [MoA]","Breast Cancer Resistance Protein Inhibitors [MoA]"],"manufacturer_name":["Stemline Therapeutics, Inc."],"application_number":["NDA217639"],"is_original_packager":[true]},"version":"5","pregnancy":["8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available human data on ORSERDU use in pregnant women to inform the drug-associated risk. In an animal reproduction study, oral administration of elacestrant to pregnant rats during organogenesis caused embryo-fetal mortality and structural abnormalities at maternal exposures below the recommended dose based on AUC (see Data ) . Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Data Animal Data In an embryo-fetal development study in pregnant rats, administration of oral doses of elacestrant up to 30 mg/kg/day during the period of organogenesis resulted in maternal toxicity (reduced body weight gain, low food consumption, red vulvar discharge) and embryo-fetal mortality (increased resorptions, post-implantation loss, and reduced number of live fetuses) at ≥ 3 mg/kg/day (approximately 0.1 times the human AUC at the recommended dose). Additional adverse effects included reduced fetal weight and external malformations of the limbs (hyperflexion, malrotation) and head (domed, misshapen, flattened) with corresponding skeletal malformations of the skull at doses ≥ 10 mg/kg/day (approximately 0.5 times the human AUC at the recommended dose)."],"description":["11 DESCRIPTION Elacestrant hydrochloride is the salt form of elacestrant, an estrogen receptor antagonist, that has the chemical name: (6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride. Elacestrant hydrochloride is the dihydrochloride salt and the molecular formula is C 30 H 38 N 2 O 2 .2HCL. The relative molecular mass is 531.56 g/mol. The chemical structure of elacestrant hydrochloride is shown below: Elacestrant hydrochloride is a white to off-white to grey solid and is freely soluble in 0.01N HCI. ORSERDU (elacestrant) 345 mg film-coated tablet contains 400 mg of elacestrant hydrochloride (approximately 345 mg of elacestrant free base). ORSERDU (elacestrant) 86 mg film-coated tablet contains 100 mg of elacestrant hydrochloride (approximately 86 mg of elacestrant free base). Both tablet strengths contain the following inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate (non-bovine), microcrystalline cellulose, and silicified microcrystalline cellulose. The tablets also contain Opadry II Blue (polyvinyl alcohol, titanium dioxide, polyethylene glycol, FD&C Blue #1 and talc). Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING ORSERDU (elacestrant) film-coated tablets for oral use are supplied as follows: Tablet Strength Tablet Color and Shape Tablet Markings Pack Size NDC Code Elacestrant 345 mg (equivalent to 400 mg elacestrant hydrochloride) Light blue; Oval “MH” Bottle of 30 Tablets with Child Resistant Closure (CRC). NDC 72187-0102-3 Elacestrant 86 mg (equivalent to 100 mg elacestrant hydrochloride) Light blue; Round “ME” Bottle of 30 Tablets with Child Resistant Closure (CRC). NDC 72187-0101-3 Storage and Handling Store at 20°C to 25°C (68°F to 77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F). [see USP controlled room temperature]."],"geriatric_use":["8.5 Geriatric Use Of 237 patients who received ORSERDU in the EMERALD trial, 43% were 65 years of age or older and 17% were 75 years of age or older. No overall differences in safety or effectiveness of ORSERDU were observed between patients 65 years or older of age compared to younger patients. There are an insufficient number of patients 75 years of age or older to assess whether there are differences in safety or effectiveness."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of ORSERDU in pediatric patients have not been established."],"effective_time":"20240802","clinical_studies":["14 CLINICAL STUDIES The efficacy of ORSERDU was evaluated in EMERALD (NCT03778931), a randomized, open-label, active-controlled, multicenter trial that enrolled 478 postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer of which 228 patients had ESR1 mutations. Patients were required to have disease progression on one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor. Eligible patients could have received up to one prior line of chemotherapy in the advanced or metastatic setting. Patients were randomized (1:1) to receive ORSERDU 345 mg orally once daily (n=239), or investigator’s choice of endocrine therapy (n=239), which included fulvestrant (n=166), or an aromatase inhibitor (n=73; anastrozole, letrozole or exemestane). Randomization was stratified by ESR1 mutation status (detected vs not detected), prior treatment with fulvestrant (yes vs no), and visceral metastasis (yes vs no). ESR1 mutational status was determined by blood circulating tumor deoxyribonucleic acid (ctDNA) using the Guardant360 CDx assay and was limited to ESR1 missense mutations in the ligand binding domain (between codons 310 to 547). Patients were treated until disease progression or unacceptable toxicity. The major efficacy outcome was progression-free survival (PFS), assessed by a blinded imaging review committee (BIRC). An additional efficacy outcome measure was overall survival (OS). A statistically significant difference in PFS was observed in the intention to treat (ITT) population and in the subgroup of patients with ESR1 mutations. An exploratory analysis of PFS in the 250 (52%) patients without ESR1 mutations showed a HR 0.86 (95% CI: 0.63, 1.19) indicating that the improvement in the ITT population was primarily attributed to the results seen in the ESR1 mutated population. Among the patients with ESR1 mutations (n=228), the median age was 63 years (range: 28-89); 100% were female; 72% were White, 5.7% Asian, 3.5% Black, 0.4% Other, 18.4% unknown/not reported; 8.8% were Hispanic/Latino; and baseline ECOG performance status was 0 (57%) or 1 (43%). Most patients had visceral disease (71%); 62% had received 1 line of endocrine therapy and 39% had received 2 lines of endocrine therapy in the advanced or metastatic setting. All patients had received prior treatment with a CDK4/6 inhibitor, 24% had received prior fulvestrant, and 25% had received prior chemotherapy in the advanced or metastatic setting. Efficacy results are presented in Table 7 and Figure 1 for patients with ESR1 mutations. Table 7: Efficacy Results for EMERALD (Patients with ESR1 Mutations) CI=confidence interval; ESR1 =estrogen receptor 1 a PFS results based on blinded imaging review committee. b Kaplan-Meier estimate; 95% CI based on the Brookmeyer-Crowley method using a linear transformation. c Cox proportional hazards model stratified by prior treatment with fulvestrant (yes vs no) and visceral metastasis (yes vs no). d Stratified log-rank test two-sided p-value. e NS – Not statistically significant. ORSERDU (N = 115) Fulvestrant or an Aromatase Inhibitor (N=113) Progression-free Survival (PFS) a Number of PFS Events, n (%) 62 (54) 78 (69) Median PFS months b (95% CI) 3.8 (2.2, 7.3) 1.9 (1.9, 2.1) Hazard ratio c (95% CI) 0.55 (0.39, 0.77) p-value d 0.0005 Overall Survival (OS) Number of OS Events, n (%) 61 (53) 60 (53) Hazard ratio c (95% CI) 0.90 (0.63, 1.30) p-value d NS e Figure 1: Kaplan-Meier Curve for PFS in EMERALD (Patients with ESR1 Mutations, BIRC Assessment) + Censored times Figure 1"],"pharmacodynamics":["12.2 Pharmacodynamics Elacestrant exposure-response relationships and the time course of pharmacodynamics have not been fully characterized. Cardiac Electrophysiology ORSERDU does not cause a mean increase in QTc interval > 20 msec at the approved recommended dose."],"pharmacokinetics":["12.3 Pharmacokinetics The steady-state mean (%CV) maximum concentration (Cmax) of elacestrant is 119 ng/mL (43.6%) and the area under the concentration-time curve (AUC 0-24h ) is 2440 ng*h/mL (44.3%) after administration of the recommended dosage of 345 mg once daily. The C max and AUC of elacestrant increase more than proportionally over a dosage range from 43 mg to 862 mg once daily (0.125 to 2.5 times the approved recommended dosage). Steady state is reached by Day 6 and the mean accumulation ratio based on AUC 0-24h is 2-fold. Absorption The time to achieve peak plasma concentration (t max ) ranges from 1 to 4 hours. The elacestrant oral bioavailability is approximately 10%. Effect of Food Administration of ORSERDU 345 mg with a high-fat meal (800 to 1000 calories, 50% fat) increased Cmax by 42% and AUC by 22% compared to fasted administration. Distribution The estimated apparent volume of distribution is 5800L. Plasma protein binding of elacestrant is >99% and independent of concentration. Elimination The elimination half-life of elacestrant is 30 to 50 hours. The estimated mean (% CV) clearance of elacestrant is 186 L/hr (43.5%) and renal clearance is ≤ 0.14 L/hr. Metabolism Elacestrant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2A6 and CYP2C9. Excretion Following a single radiolabeled oral dose of 345 mg, 82% was recovered in feces (34% unchanged) and 7.5% was recovered in urine (< 1% unchanged). Specific Populations There were no clinically significant differences in the pharmacokinetics of elacestrant based on age (24 to 89 years), sex, and body weight (41 to 143 kg). Patients with Hepatic Impairment There were no clinically significant differences in the Cmax and AUC of elacestrant in subjects with mild hepatic impairment (Child-Pugh A). The AUC of elacestrant increased in subjects with moderate hepatic impairment (Child-Pugh B) by 83%. Elacestrant has not been studied in subjects with severe hepatic impairment (Child-Pugh C). Drug Interaction Studies Clinical Studies There were no clinically significant differences in the pharmacokinetics of elacestrant when used concomitantly with cimetidine (weak CYP3A inhibitor), omeprazole (gastric acid-reducing agent), or warfarin (highly protein-bound drug). Table 5 describes the effect of other drugs on the pharmacokinetics of elacestrant and Table 6 describes the effect of elacestrant on the pharmacokinetics of other drugs. Table 5: Effect of Other Drugs on Elacestrant a Predicted changes in C max and AUC of elacestrant. Concomitant Drug Elacestrant Dose Fold Increased or Percent Decrease of Elacestrant With Concomitant Drug C max AUC CYP3A Inhibitors Strong Inhibitor Itraconazole 172 mg once daily 4.4 5.3 Moderate Inhibitor Fluconazole a 345 mg single dose 1.6 2.3 CYP3A Inducers Strong Inducer Rifampin 345 mg single dose 73% 86% Moderate Inducer Efavirenz a 345 mg single dose 44-63% 55-73% Table 6: Effect of Elacestrant on Other Drugs Concomitant Drug Elacestrant Dose Fold Increase of Concomitant Drug With Elacestrant C max AUC Substrate of P-gp Digoxin 345 mg single dose 1.3 1.1 Substrate of BCRP Rosuvastatin 345 mg single dose 1.5 1.2 In Vitro Studies Cytochrome P450 (CYP) Enzymes: Elacestrant is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A. Elacestrant is not an inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, or CYP3A. Transporter Systems: Elacestrant is a substrate for OATP2B1, but not P-gp. Elacestrant is not an inhibitor of OAT1, OAT3, OCT2, MATE1, MATE2-K, OCT1, OATP1B1, OATP1B3 or OATP2B1."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Dyslipidemia [see Warnings and Precautions ( 5.1 )] The most common (>10%) adverse reactions, including laboratory abnormalities, of ORSERDU were musculoskeletal pain, nausea, increased cholesterol, increased AST, increased triglycerides, fatigue, decreased hemoglobin, vomiting, increased ALT, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, and dyspepsia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of ORSERDU was evaluated in 467 patients with ER+/HER2- advanced breast cancer following CDK4/6 inhibitor therapy in EMERALD, a randomized, open-label, multicenter study [see Clinical Studies ( 14 )] . Patients received ORSERDU 345 mg orally once daily (n=237) or standard of care (SOC) consisting of fulvestrant or an aromatase inhibitor (n=230). Among patients who received ORSERDU, 22% were exposed for 6 months or longer and 9% were exposed for greater than one year. Serious adverse reactions occurred in 12% of patients who received ORSERDU. Serious adverse reactions in >1% of patients who received ORSERDU were musculoskeletal pain (1.7%) and nausea (1.3%). Fatal adverse reactions occurred in 1.7% of patients who received ORSERDU, including cardiac arrest, septic shock, diverticulitis, and unknown cause (one patient each). Permanent discontinuation of ORSERDU due to an adverse reaction occurred in 6% of patients. Adverse reactions which resulted in permanent discontinuation of ORSERDU in >1% of patients were musculoskeletal pain (1.7%) and nausea (1.3%). Dosage interruptions of ORSERDU due to an adverse reaction occurred in 15% of patients. Adverse reactions which resulted in dosage interruption of ORSERDU in >1% of patients were nausea (3.4%), musculoskeletal pain (1.7%), and increased ALT (1.3%). Dosage reductions of ORSERDU due to an adverse reaction occurred in 3% of patients. Adverse reactions which required dosage reductions of ORSERDU in >1% of patients were nausea (1.7%). The most common (≥10%) adverse reactions, including laboratory abnormalities, of ORSERDU were musculoskeletal pain, nausea, increased cholesterol, increased AST, increased triglycerides, fatigue, decreased hemoglobin, vomiting, increased ALT, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, and dyspepsia. Table 3 summarizes the adverse reactions in EMERALD. Table 3: Adverse Reactions (>10%) in Patients with ER-positive, HER2-negative, Advanced or Metastatic Breast Cancer Who Received ORSERDU in EMERALD a a Adverse reactions were graded using NCI CTCAE version 5.0. b Includes other related terms c Only includes Grade 3 adverse reactions. Adverse Reaction ORSERDU (n=237) Fulvestrant or an Aromatase Inhibitor (n=230) All Grades (%) Grade 3 or 4 c (%) All Grades (%) Grade 3 or 4 c (%) Musculoskeletal and connective tissue disorders Musculoskeletal pain b 41 7 39 1 Gastrointestinal disorders Nausea 35 2.5 19 0.9 Vomiting b 19 0.8 9 0 Diarrhea 13 0 10 1 Constipation 12 0 6 0 Abdominal pain b 11 1 10 0.9 Dyspepsia 10 0 2.6 0 General disorders Fatigue b 26 2 27 1 Metabolism and nutrition disorders Decreased appetite 15 0.8 10 0.4 Nervous system Headache 12 2 12 0 Vascular disorders Hot flush 11 0 8 0 Clinically relevant adverse reactions in < 10% of patients who received ORSERDU included rash, insomnia, dyspnea, cough, dizziness, stomatitis and gastroesophageal reflux disease. Table 4 summarizes the laboratory abnormalities in EMERALD. Table 4: Select Laboratory Abnormalities (>10%) That Worsened from Baseline in Patients with ER-positive, HER2-negative, Advanced or Metastatic Breast Cancer Who Received ORSERDU in EMERALD a a The denominator used to calculate the rate varied from 29 to 236 for ORSERDU and from 37 to 225 for fulvestrant or an aromatase inhibitor based on the number of patients with a baseline value and at least one post-treatment value. Laboratory Abnormality ORSERDU a Fulvestrant or an Aromatase Inhibitor a All Grades (%) Grade 3 or 4 (%) All Grades (%) Grade 3 or 4 (%) Chemistry Cholesterol increased 30 1 17 0 Aspartate aminotransferase increased 29 0 34 1 Triglycerides increased 27 2 15 1 Alanine aminotransferase increased 17 0 24 1 Sodium decreased 16 1 15 0 Creatinine increased 16 0 6 0 Hematology Hemoglobin decreased 26 1 20 2"],"contraindications":["4 CONTRAINDICATIONS None. None ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Strong and Moderate CYP3A4 Inducers : Avoid concomitant use with ORSERDU ( 7.1 ) Strong and Moderate CYP3A4 Inhibitors : Avoid concomitant use with ORSERDU ( 7.1 ) 7.1 Effect of Other Drugs on ORSERDU Strong and Moderate CYP3A4 Inhibitors Avoid concomitant use of strong or moderate CYP3A inhibitors with ORSERDU. Elacestrant is a CYP3A4 substrate. Concomitant use of a strong or moderate CYP3A4 inhibitor increase elacestrant exposure [see Clinical Pharmacology ( 12.3 )] , which may increase the risk of adverse reactions of ORSERDU. Strong and Moderate CYP3A4 Inducers Avoid concomitant use of strong or moderate CYP3A inducers with ORSERDU. Elacestrant is a CYP3A4 substrate. Concomitant use of a strong or moderate CYP3A4 inducer decreases elacestrant exposure [see Clinical Pharmacology ( 12.3 )] , which may decrease effectiveness of ORSERDU. 7.2 Effect of ORSERDU on Other Drugs P-gp Substrates Reduce the dosage of P-gp substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions. Elacestrant is a P-gp inhibitor. Concomitant use of ORSERDU with a P-gp substrate increased the concentrations of P-gp substrate [see Clinical Pharmacology ( 12.3 )] , which may increase the adverse reactions associated with a P-gp substrate. BCRP Substrates Reduce the dosage of BCRP substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions. Elacestrant is a BCRP inhibitor. Concomitant use of ORSERDU with a BCRP substrate increased the plasma concentrations of BCRP substrate [see Clinical Pharmacology ( 12.3 )] , which may increase the adverse reactions associated with a BCRP substrate."],"how_supplied_table":["
Tablet Strength Tablet Color and ShapeTablet MarkingsPack SizeNDC Code
Elacestrant 345 mg (equivalent to 400 mg elacestrant hydrochloride)Light blue; Oval“MH”Bottle of 30 Tablets with Child Resistant Closure (CRC).NDC 72187-0102-3
Elacestrant 86 mg (equivalent to 100 mg elacestrant hydrochloride) Light blue; Round“ME”Bottle of 30 Tablets with Child Resistant Closure (CRC).NDC 72187-0101-3
"],"mechanism_of_action":["12.1 Mechanism of Action Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). In ER-positive (ER+) HER2-negative (HER2-) breast cancer cells, elacestrant inhibited 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway. Elacestrant demonstrated in vitro and in vivo antitumor activity including in ER+ HER2- breast cancer models resistant to fulvestrant and cyclin-dependent kinase 4/6 inhibitors and those harboring estrogen receptor 1 gene ( ESR1 ) mutations."],"storage_and_handling":["Storage and Handling Store at 20°C to 25°C (68°F to 77°F). Excursions permitted from 15°C to 30°C (59°F to 86°F). [see USP controlled room temperature]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα). In ER-positive (ER+) HER2-negative (HER2-) breast cancer cells, elacestrant inhibited 17β-estradiol mediated cell proliferation at concentrations inducing degradation of ERα protein mediated through proteasomal pathway. Elacestrant demonstrated in vitro and in vivo antitumor activity including in ER+ HER2- breast cancer models resistant to fulvestrant and cyclin-dependent kinase 4/6 inhibitors and those harboring estrogen receptor 1 gene ( ESR1 ) mutations. 12.2 Pharmacodynamics Elacestrant exposure-response relationships and the time course of pharmacodynamics have not been fully characterized. Cardiac Electrophysiology ORSERDU does not cause a mean increase in QTc interval > 20 msec at the approved recommended dose. 12.3 Pharmacokinetics The steady-state mean (%CV) maximum concentration (Cmax) of elacestrant is 119 ng/mL (43.6%) and the area under the concentration-time curve (AUC 0-24h ) is 2440 ng*h/mL (44.3%) after administration of the recommended dosage of 345 mg once daily. The C max and AUC of elacestrant increase more than proportionally over a dosage range from 43 mg to 862 mg once daily (0.125 to 2.5 times the approved recommended dosage). Steady state is reached by Day 6 and the mean accumulation ratio based on AUC 0-24h is 2-fold. Absorption The time to achieve peak plasma concentration (t max ) ranges from 1 to 4 hours. The elacestrant oral bioavailability is approximately 10%. Effect of Food Administration of ORSERDU 345 mg with a high-fat meal (800 to 1000 calories, 50% fat) increased Cmax by 42% and AUC by 22% compared to fasted administration. Distribution The estimated apparent volume of distribution is 5800L. Plasma protein binding of elacestrant is >99% and independent of concentration. Elimination The elimination half-life of elacestrant is 30 to 50 hours. The estimated mean (% CV) clearance of elacestrant is 186 L/hr (43.5%) and renal clearance is ≤ 0.14 L/hr. Metabolism Elacestrant is primarily metabolized by CYP3A4 and to a lesser extent by CYP2A6 and CYP2C9. Excretion Following a single radiolabeled oral dose of 345 mg, 82% was recovered in feces (34% unchanged) and 7.5% was recovered in urine (< 1% unchanged). Specific Populations There were no clinically significant differences in the pharmacokinetics of elacestrant based on age (24 to 89 years), sex, and body weight (41 to 143 kg). Patients with Hepatic Impairment There were no clinically significant differences in the Cmax and AUC of elacestrant in subjects with mild hepatic impairment (Child-Pugh A). The AUC of elacestrant increased in subjects with moderate hepatic impairment (Child-Pugh B) by 83%. Elacestrant has not been studied in subjects with severe hepatic impairment (Child-Pugh C). Drug Interaction Studies Clinical Studies There were no clinically significant differences in the pharmacokinetics of elacestrant when used concomitantly with cimetidine (weak CYP3A inhibitor), omeprazole (gastric acid-reducing agent), or warfarin (highly protein-bound drug). Table 5 describes the effect of other drugs on the pharmacokinetics of elacestrant and Table 6 describes the effect of elacestrant on the pharmacokinetics of other drugs. Table 5: Effect of Other Drugs on Elacestrant a Predicted changes in C max and AUC of elacestrant. Concomitant Drug Elacestrant Dose Fold Increased or Percent Decrease of Elacestrant With Concomitant Drug C max AUC CYP3A Inhibitors Strong Inhibitor Itraconazole 172 mg once daily 4.4 5.3 Moderate Inhibitor Fluconazole a 345 mg single dose 1.6 2.3 CYP3A Inducers Strong Inducer Rifampin 345 mg single dose 73% 86% Moderate Inducer Efavirenz a 345 mg single dose 44-63% 55-73% Table 6: Effect of Elacestrant on Other Drugs Concomitant Drug Elacestrant Dose Fold Increase of Concomitant Drug With Elacestrant C max AUC Substrate of P-gp Digoxin 345 mg single dose 1.3 1.1 Substrate of BCRP Rosuvastatin 345 mg single dose 1.5 1.2 In Vitro Studies Cytochrome P450 (CYP) Enzymes: Elacestrant is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A. Elacestrant is not an inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, or CYP3A. Transporter Systems: Elacestrant is a substrate for OATP2B1, but not P-gp. Elacestrant is not an inhibitor of OAT1, OAT3, OCT2, MATE1, MATE2-K, OCT1, OATP1B1, OATP1B3 or OATP2B1."],"indications_and_usage":["1 INDICATIONS AND USAGE ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. ORSERDU is an estrogen receptor antagonist indicated for: treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Dyslipidemia: ORSERDU may cause hypercholesterolemia and hypertriglyceridemia. Monitor lipid profile prior to starting treatment and periodically thereafter. ( 5.1 ) Embryo-Fetal Toxicity: ORSERDU can cause fetal harm. Advise of the potential risk to a fetus and to use effective contraception. ( 5.2 , 8.1 , 8.3 ) 5.1 Dyslipidemia Hypercholesterolemia and hypertriglyceridemia occurred in patients taking ORSERDU at an incidence of 30% and 27%, respectively. The incidence of Grade 3 and 4 hypercholesterolemia and hypertriglyceridemia were 0.9% and 2.2%, respectively [see Adverse Reactions ( 6.1 )] . Monitor lipid profile prior to starting and periodically while taking ORSERDU. 5.2 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman. Administration of elacestrant to pregnant rats resulted in adverse developmental outcomes, including embryo-fetal mortality and structural abnormalities, at maternal exposures below the recommended dose based on area under the curve (AUC). Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )] ."],"clinical_studies_table":["
CI=confidence interval; ESR1=estrogen receptor 1
aPFS results based on blinded imaging review committee.
bKaplan-Meier estimate; 95% CI based on the Brookmeyer-Crowley method using a linear transformation.
cCox proportional hazards model stratified by prior treatment with fulvestrant (yes vs no) and visceral metastasis (yes vs no).
dStratified log-rank test two-sided p-value.
eNS – Not statistically significant.
ORSERDU (N = 115)Fulvestrant or an Aromatase Inhibitor (N=113)
Progression-free Survival (PFS)a
Number of PFS Events, n (%)62 (54)78 (69)
Median PFS monthsb (95% CI)3.8 (2.2, 7.3)1.9 (1.9, 2.1)
Hazard ratioc (95% CI)0.55 (0.39, 0.77)
p-valued0.0005
Overall Survival (OS)
Number of OS Events, n (%)61 (53)60 (53)
Hazard ratioc (95% CI)0.90 (0.63, 1.30)
p-valuedNSe
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with elacestrant. Elacestrant was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in either in vitro chromosome aberration assays or an in vivo rat bone marrow micronucleus assay. Fertility studies with elacestrant in animals have not been conducted. In repeated-dose toxicity studies up to 26 weeks duration in rats and 39 weeks duration in cynomolgus monkeys, adverse reactions were observed in female reproductive organs including atrophy of the vagina, cervix, and uterus and follicular cysts in the ovary at doses ≥ 10 mg/kg/day in rats and cynomolgus monkeys (≥ 0.3 times the human AUC at the recommended dose). Decreased cellularity of Leydig cells and degeneration/atrophy of the seminiferous epithelium in the testis were observed in male rats at a dose of 50 mg/kg/day (approximately 2.6 times the human AUC at the recommended dose)."],"pharmacokinetics_table":["
aPredicted changes in Cmax and AUC of elacestrant.
Concomitant DrugElacestrant DoseFold Increased or Percent Decrease of Elacestrant With Concomitant Drug
CmaxAUC
CYP3A Inhibitors
Strong Inhibitor Itraconazole 172 mg once daily4.45.3
Moderate Inhibitor Fluconazolea345 mg single dose1.62.3
CYP3A Inducers
Strong Inducer Rifampin345 mg single dose73%86%
Moderate Inducer Efavirenza345 mg single dose44-63%55-73%
","
Concomitant DrugElacestrant DoseFold Increase of Concomitant Drug With Elacestrant
CmaxAUC
Substrate of P-gp
Digoxin345 mg single dose1.31.1
Substrate of BCRP
Rosuvastatin 345 mg single dose1.51.2
"],"adverse_reactions_table":["
aAdverse reactions were graded using NCI CTCAE version 5.0.
bIncludes other related terms
cOnly includes Grade 3 adverse reactions.
Adverse ReactionORSERDU (n=237)Fulvestrant or an Aromatase Inhibitor (n=230)
All Grades (%)Grade 3 or 4 c (%)All Grades (%)Grade 3 or 4 c (%)
Musculoskeletal and connective tissue disorders
Musculoskeletal painb417391
Gastrointestinal disorders
Nausea352.5190.9
Vomitingb190.890
Diarrhea130101
Constipation12060
Abdominal painb111100.9
Dyspepsia1002.60
General disorders
Fatigueb262271
Metabolism and nutrition disorders
Decreased appetite150.8100.4
Nervous system
Headache122120
Vascular disorders
Hot flush11080
","
aThe denominator used to calculate the rate varied from 29 to 236 for ORSERDU and from 37 to 225 for fulvestrant or an aromatase inhibitor based on the number of patients with a baseline value and at least one post-treatment value.
Laboratory AbnormalityORSERDUaFulvestrant or an Aromatase Inhibitora
All Grades (%)Grade 3 or 4 (%)All Grades (%)Grade 3 or 4 (%)
Chemistry
Cholesterol increased301170
Aspartate aminotransferase increased290341
Triglycerides increased272151
Alanine aminotransferase increased170241
Sodium decreased161150
Creatinine increased16060
Hematology
Hemoglobin decreased261202
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Dyslipidemia Advise patients that hypercholesterolemia and hypertriglyceridemia may occur while taking ORSERDU. Inform patients that lipid profile monitoring will be performed prior to starting and periodically while taking ORSERDU [see Warnings and Precautions ( 5.1 ) and Adverse Reactions ( 6.1 )] . Embryo-Fetal Toxicity Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.2 ) and Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose [see Use in Specific Populations ( 8.3 )] . Lactation Advise women not to breastfeed during treatment with ORSERDU and for 1 week after the last dose [see Use in Specific Populations ( 8.2 )] . Infertility Advise males and females of reproductive potential that ORSERDU may impair fertility [see Use in Specific Populations ( 8.3 )] . Drug Interactions Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, and herbal products [see Drug Interactions ( 7.1 , 7.2 )] . Other Common Adverse Reactions Advise patients that other adverse reactions with ORSERDU treatment may include musculoskeletal pain, nausea, fatigue, vomiting, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, and dyspepsia, [see Adverse Reactions ( 6.1 )] . Dosing Instructions Instruct patients to take ORSERDU at approximately the same time each day and to swallow the tablet(s) whole. Tablets should not be chewed, crushed, or split prior to swallowing [see Dosage and Administration ( 2.2 )] . Advise patients to take ORSERDU with food to reduce nausea and vomiting [see Dosage and Administration ( 2.2 ) and Adverse Reactions ( 6.1 )] . Instruct patients that if a dose of ORSERDU is missed for more than 6 hours or vomiting occurs, skip the dose and take the next dose the following day at its regularly scheduled time [see Dosage and Administration ( 2.2 )] . ORSERDU is a trademark of the Menarini Group. ©Stemline Therapeutics, Inc., a Menarini Group company Manufactured for: Stemline Therapeutics, Inc., New York, NY 10022"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Select patients for treatment with ORSERDU based on the presence of ESR1 mutations. ( 2.1 ) The recommended dosage of ORSERDU is one 345 mg tablet taken orally, once daily, with food ( 2.2 ) Dose interruption, reduction, or permanent discontinuation may be required due to adverse reactions. ( 2.3 ) 2.1 Patient Selection Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with ORSERDU based on the presence of ESR1 mutation(s) in plasma specimen using an FDA-approved test [see Indications and Usage ( 1 ) and Clinical Studies ( 14 )] . Information on FDA-approved tests for detection of ESR1 mutations in breast cancer is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage The recommended dosage of ORSERDU is 345 mg taken orally with food once daily until disease progression or unacceptable toxicity occurs. Take ORSERDU at approximately the same time each day. Take with food to reduce nausea and vomiting [see Adverse Reactions ( 6.1 )] . Swallow ORSERDU tablet(s) whole. Do not chew, crush, or split prior to swallowing. Do not take any ORSERDU tablets that are broken, cracked, or that look damaged. If a dose is missed for more than 6 hours or vomiting occurs, skip the dose and take the next dose the following day at its regularly scheduled time. 2.3 Dosage Modifications for Adverse Reactions The recommended dose reduction levels for adverse reactions are listed in Table 1 : Table 1: ORSERDU Dose Reduction Levels for Adverse Reactions 1 If further dose reduction below 172 mg once daily is required, permanently discontinue ORSERDU. Dose Reduction Dosage Number and Strength of Tablets First-dose reduction 258 mg once daily Three 86 mg tablets Second-dose reduction 172 mg once daily 1 Two 86 mg tablets Recommended dosage modifications of ORSERDU for adverse reactions are provided in Table 2 [see Adverse Reactions ( 6.1 )] . Table 2: ORSERDU Dosage Modification Guidelines for Adverse Reactions Severity Dosage Modification Grade 1 Continue ORSERDU at current dose level. Grade 2 Consider interruption of ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU at the same dose level. Grade 3 Interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU at the next lower dose level. If the Grade 3 toxicity recurs, interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU reduced by another dose level. Grade 4 Interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU reduced by one dose level. If a Grade 4 or intolerable adverse reaction recurs, permanently discontinue ORSERDU. 2.4 Dosage Modifications for Use with Concomitant CYP3A4 Inducers and Inhibitors Avoid concomitant use of ORSERDU with strong or moderate CYP3A4 inducers and inhibitors [see Drug Interactions ( 7.1 )] . 2.5 Dosage Modifications for Hepatic Impairment Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the ORSERDU dosage to 258 mg once daily for patients with moderate hepatic impairment (Child-Pugh B). No dosage adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A) [see Clinical Pharmacology ( 12.3 )] ."],"spl_product_data_elements":["ORSERDU Elacestrant ELACESTRANT ELACESTRANT Blue Biconvex ME ORSERDU Elacestrant ELACESTRANT ELACESTRANT Blue Biconvex MH"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets: Elacestrant 345 mg (equivalent to 400 mg elacestrant hydrochloride) and 86 mg (equivalent to 100 mg elacestrant hydrochloride): 345 mg: light blue, unscored, oval film-coated biconvex tablet, imprinted with “MH” on one side and plain on the other side. 86 mg: light blue, unscored, round film-coated biconvex tablet, imprinted with “ME” on one side and plain on the other side. Tablets: 345 mg and 86 mg ( 3 )"],"spl_patient_package_insert":["This Patient Information has been approved by the U.S. Food and Drug Administration. Issued: 01/2023 PATIENT INFORMATION ORSERDU™ (or-SER-doo) (elacestrant) tablets What is ORSERDU? ORSERDU is a prescription medicine to treat women who have gone through menopause and adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1 -mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after endocrine therapy. Your healthcare provider will perform a test to make sure that ORSERDU is right for you. It is not known if ORSERDU is safe and effective in children. Before taking ORSERDU, tell your healthcare provider about all of your medical conditions, including if you: have liver problems are pregnant or plan to become pregnant. ORSERDU can harm your unborn baby. Females who are able to become pregnant: Your healthcare provider may do a pregnancy test before you start treatment with ORSERDU. You should use effective (contraception) birth control during treatment with ORSERDU and for 1 week after the last dose. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ORSERDU. Males with female partners who are able to become pregnant: You should use effective (contraception) birth control during treatment with ORSERDU and for 1 week after the last dose. are breastfeeding or plan to breastfeed. It is not known if ORSERDU passes into your breast milk. Do not breastfeed during treatment with ORSERDU and for 1 week after the last dose. Tell your healthcare provider about all of the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. ORSERDU and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine. How should I take ORSERDU? Take ORSERDU exactly as your healthcare provider tells you. Do not change your dose or stop taking ORSERDU unless your healthcare provider tells you. Take ORSERDU 1 time each day, at about the same time each day. Take ORSERDU with food. Taking ORSERDU with food may help reduce nausea and vomiting. Swallow ORSERDU tablets whole. Do not chew, crush or split the tablets before swallowing. Do not take any ORSERDU tablets that are broken, cracked, or that look damaged. If you miss a dose of ORSERDU or vomit after taking a dose of ORSERDU, do not take another dose of ORSERDU on that day. Skip the dose and take your next dose the following day at your regularly scheduled time. What are the possible side effects of ORSERDU? ORSERDU may cause serious side effects, including: Increased fat (lipid) levels in your blood (hypercholesterolemia and hypertriglyceridemia) . Your healthcare provider will do blood tests to check your lipid levels before and during your treatment with ORSERDU. The most common side effects of ORSERDU include: muscle and joint (musculoskeletal) pain nausea increased cholesterol and triglyceride levels in your blood increased liver function tests tiredness decreased red blood cell counts vomiting decreased salt (sodium) levels in your blood increased kidney function test decreased appetite diarrhea headache constipation stomach-area (abdominal) pain hot flush indigestion or heartburn Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with ODSERDU, if you develop certain side effects. ORSERDU may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ORSERDU. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store ORSERDU? Store ORSERDU at room temperature 68℉ to 77℉ (20℃ to 25℃). Keep ORSERDU and all medicines out of the reach of children. General information about the safe and effective use of ORSERDU. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ORSERDU for a condition for which it was not prescribed. Do not give ORSERDU to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about ORSERDU that is written for health professionals. What are the ingredients in ORSERDU? Active ingredient : elacestrant Inactive ingredients : colloidal silicon dioxide, crospovidone, magnesium stearate (non-bovine), microcrystalline cellulose, silicified microcrystalline cellulose and Opadry II Blue (polyvinyl alcohol, titanium dioxide, polyethylene glycol, FD&C Blue #1 and talc). ORSERDU is a trademark of the Menarini Group. ©Stemline Therapeutics, Inc., a Menarini Group Company Manufactured for: Stemline Therapeutics, Inc., New York, NY 10022 For more information, go to www.ORSERDU.com or call 1-877-332-7961"],"clinical_pharmacology_table":["
aPredicted changes in Cmax and AUC of elacestrant.
Concomitant DrugElacestrant DoseFold Increased or Percent Decrease of Elacestrant With Concomitant Drug
CmaxAUC
CYP3A Inhibitors
Strong Inhibitor Itraconazole 172 mg once daily4.45.3
Moderate Inhibitor Fluconazolea345 mg single dose1.62.3
CYP3A Inducers
Strong Inducer Rifampin345 mg single dose73%86%
Moderate Inducer Efavirenza345 mg single dose44-63%55-73%
","
Concomitant DrugElacestrant DoseFold Increase of Concomitant Drug With Elacestrant
CmaxAUC
Substrate of P-gp
Digoxin345 mg single dose1.31.1
Substrate of BCRP
Rosuvastatin 345 mg single dose1.51.2
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation : Advise not to breastfeed. ( 8.2 ) Hepatic impairment : Avoid use in patients with severe hepatic impairment (Child-Pugh C). Reduce the dosage for patients with moderate hepatic impairment (Child-Pugh B). ( 2.5 , 8.6 ) 8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available human data on ORSERDU use in pregnant women to inform the drug-associated risk. In an animal reproduction study, oral administration of elacestrant to pregnant rats during organogenesis caused embryo-fetal mortality and structural abnormalities at maternal exposures below the recommended dose based on AUC (see Data ) . Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. Data Animal Data In an embryo-fetal development study in pregnant rats, administration of oral doses of elacestrant up to 30 mg/kg/day during the period of organogenesis resulted in maternal toxicity (reduced body weight gain, low food consumption, red vulvar discharge) and embryo-fetal mortality (increased resorptions, post-implantation loss, and reduced number of live fetuses) at ≥ 3 mg/kg/day (approximately 0.1 times the human AUC at the recommended dose). Additional adverse effects included reduced fetal weight and external malformations of the limbs (hyperflexion, malrotation) and head (domed, misshapen, flattened) with corresponding skeletal malformations of the skull at doses ≥ 10 mg/kg/day (approximately 0.5 times the human AUC at the recommended dose). 8.2 Lactation Risk Summary There are no data on the presence of elacestrant in human milk, its effects on milk production, or the breastfed child. Because of the potential for serious adverse reactions in the breastfed child, advise lactating women to not breastfeed during treatment with ORSERDU and for 1 week after the last dose. 8.3 Females and Males of Reproductive Potential ORSERDU can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )] . Pregnancy Testing Verify the pregnancy status in females of reproductive potential prior to initiating ORSERDU treatment. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Males Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ORSERDU and for 1 week after the last dose. Infertility Based on findings from animal studies, ORSERDU may impair fertility in females and males of reproductive potential [see Nonclinical Toxicology ( 13.1 )] . 8.4 Pediatric Use The safety and effectiveness of ORSERDU in pediatric patients have not been established. 8.5 Geriatric Use Of 237 patients who received ORSERDU in the EMERALD trial, 43% were 65 years of age or older and 17% were 75 years of age or older. No overall differences in safety or effectiveness of ORSERDU were observed between patients 65 years or older of age compared to younger patients. There are an insufficient number of patients 75 years of age or older to assess whether there are differences in safety or effectiveness. 8.6 Hepatic Impairment Avoid use of ORSERDU in patients with severe hepatic impairment (Child-Pugh C). Reduce the dose of ORSERDU in patients with moderate hepatic impairment (Child-Pugh B). No dosage adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A) [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3 )] ."],"dosage_and_administration_table":["
1 If further dose reduction below 172 mg once daily is required, permanently discontinue ORSERDU.
Dose ReductionDosageNumber and Strength of Tablets
First-dose reduction258 mg once dailyThree 86 mg tablets
Second-dose reduction172 mg once daily1Two 86 mg tablets
","
SeverityDosage Modification
Grade 1Continue ORSERDU at current dose level.
Grade 2Consider interruption of ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU at the same dose level.
Grade 3Interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU at the next lower dose level. If the Grade 3 toxicity recurs, interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU reduced by another dose level.
Grade 4Interrupt ORSERDU until recovery to Grade ≤ 1 or baseline. Then resume ORSERDU reduced by one dose level. If a Grade 4 or intolerable adverse reaction recurs, permanently discontinue ORSERDU.
"],"spl_patient_package_insert_table":["
This Patient Information has been approved by the U.S. Food and Drug Administration.Issued: 01/2023
PATIENT INFORMATIONORSERDU™ (or-SER-doo) (elacestrant) tablets
What is ORSERDU?ORSERDU is a prescription medicine to treat women who have gone through menopause and adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), and whose disease has progressed after endocrine therapy. Your healthcare provider will perform a test to make sure that ORSERDU is right for you. It is not known if ORSERDU is safe and effective in children.
Before taking ORSERDU, tell your healthcare provider about all of your medical conditions, including if you:have liver problemsare pregnant or plan to become pregnant. ORSERDU can harm your unborn baby. Females who are able to become pregnant:Your healthcare provider may do a pregnancy test before you start treatment with ORSERDU.You should use effective (contraception) birth control during treatment with ORSERDU and for 1 week after the last dose.Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ORSERDU.Males with female partners who are able to become pregnant:You should use effective (contraception) birth control during treatment with ORSERDU and for 1 week after the last dose.are breastfeeding or plan to breastfeed. It is not known if ORSERDU passes into your breast milk. Do not breastfeed during treatment with ORSERDU and for 1 week after the last dose.Tell your healthcare provider about all of the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements. ORSERDU and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
How should I take ORSERDU?Take ORSERDU exactly as your healthcare provider tells you.Do not change your dose or stop taking ORSERDU unless your healthcare provider tells you.Take ORSERDU 1 time each day, at about the same time each day.Take ORSERDU with food. Taking ORSERDU with food may help reduce nausea and vomiting.Swallow ORSERDU tablets whole. Do not chew, crush or split the tablets before swallowing.Do not take any ORSERDU tablets that are broken, cracked, or that look damaged.If you miss a dose of ORSERDU or vomit after taking a dose of ORSERDU, do not take another dose of ORSERDU on that day. Skip the dose and take your next dose the following day at your regularly scheduled time.
What are the possible side effects of ORSERDU?ORSERDU may cause serious side effects, including:Increased fat (lipid) levels in your blood (hypercholesterolemia and hypertriglyceridemia). Your healthcare provider will do blood tests to check your lipid levels before and during your treatment with ORSERDU.The most common side effects of ORSERDU include:muscle and joint (musculoskeletal) painnauseaincreased cholesterol and triglyceride levels in your bloodincreased liver function teststirednessdecreased red blood cell countsvomitingdecreased salt (sodium) levels in your bloodincreased kidney function testdecreased appetitediarrheaheadacheconstipationstomach-area (abdominal) painhot flushindigestion or heartburnYour healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with ODSERDU, if you develop certain side effects. ORSERDU may affect fertility in males and in females who are able to become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of ORSERDU. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ORSERDU?Store ORSERDU at room temperature 68℉ to 77℉ (20℃ to 25℃).Keep ORSERDU and all medicines out of the reach of children.
General information about the safe and effective use of ORSERDU.Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ORSERDU for a condition for which it was not prescribed. Do not give ORSERDU to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for more information about ORSERDU that is written for health professionals.
What are the ingredients in ORSERDU?Active ingredient: elacestrantInactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate (non-bovine), microcrystalline cellulose, silicified microcrystalline cellulose and Opadry II Blue (polyvinyl alcohol, titanium dioxide, polyethylene glycol, FD&C Blue #1 and talc). ORSERDU is a trademark of the Menarini Group.©Stemline Therapeutics, Inc., a Menarini Group CompanyManufactured for: Stemline Therapeutics, Inc., New York, NY 10022For more information, go to www.ORSERDU.com or call 1-877-332-7961
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - NDC:72187-0101-3 - Orserdu Bottle Label - 86mg NDC 72187-0101-3 Orserdu ® (elacestrant) tablets 86 mg Rx Only 30 Tablets Orserdu Bottle Label - 86mg","PRINCIPAL DISPLAY PANEL - NDC: 72187-0102-3 - Orserdu Bottle Label - 345mg NDC 72187-0102-3 Orserdu ® (elacestrant) tablets 345 mg Rx Only 30 Tablets Orserdu Bottle Label - 345mg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with elacestrant. Elacestrant was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay or clastogenic in either in vitro chromosome aberration assays or an in vivo rat bone marrow micronucleus assay. Fertility studies with elacestrant in animals have not been conducted. In repeated-dose toxicity studies up to 26 weeks duration in rats and 39 weeks duration in cynomolgus monkeys, adverse reactions were observed in female reproductive organs including atrophy of the vagina, cervix, and uterus and follicular cysts in the ovary at doses ≥ 10 mg/kg/day in rats and cynomolgus monkeys (≥ 0.3 times the human AUC at the recommended dose). Decreased cellularity of Leydig cells and degeneration/atrophy of the seminiferous epithelium in the testis were observed in male rats at a dose of 50 mg/kg/day (approximately 2.6 times the human AUC at the recommended dose)."]},"tags":[{"label":"Estrogen Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Estrogen receptor","category":"target"},{"label":"ESR1","category":"gene"},{"label":"ESR2","category":"gene"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"ESR1-mutated advanced or metastatic breast cancer","category":"indication"},{"label":"Estrogen receptor positive advanced or metastatic breast cancer","category":"indication"},{"label":"HER2-negative advanced or metastatic breast cancer","category":"indication"},{"label":"Stemline Therap","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1475 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1099 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"779 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"668 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"548 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"507 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"482 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"392 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"372 reports"},{"date":"","signal":"DECREASED APPETITE","source":"FDA FAERS","actionTaken":"369 reports"}],"commonSideEffects":[{"effect":"Musculoskeletal pain","drugRate":"22%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"12%","severity":"serious","_validated":true},{"effect":"Increased cholesterol","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Increased AST","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Increased triglycerides","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Fatigue","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Decreased hemoglobin","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Increased ALT","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Decreased sodium","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Increased creatinine","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Decreased appetite","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Headache","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Constipation","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Abdominal pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Hot flush","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dyspepsia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Insomnia","drugRate":"reported","severity":"unknown"},{"effect":"Dyspnea","drugRate":"reported","severity":"unknown"},{"effect":"Cough","drugRate":"reported","severity":"unknown"},{"effect":"Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Stomatitis","drugRate":"reported","severity":"unknown"},{"effect":"Gastroesophageal reflux disease","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Lactation":"There are no data on the presence of elacestrant in human milk, its effects on milk production, or the breastfed child. Because of the potential for serious adverse reactions in the breastfed child, advise lactating women to not breastfeed during treatment with ORSERDU and for week after the last dose.","Pregnancy":"Risk SummaryBased on findings in animals and its mechanism of action, ORSERDU can cause fetal harm when administered to pregnant woman [see Clinical Pharmacology (12.1)]. There are no available human data on ORSERDU use in pregnant women to inform the drug-associated risk. In an animal reproduction study, oral administration of elacestrant to pregnant rats during organogenesis caused embryo-fetal mortality and structural abnormalities at maternal exposures below the recommended dose based on AUC (see Data). Advise pregnant women and females of reproductive potential of the potential risk to fetus.The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.","Geriatric use":"Of 237 patients who received ORSERDU in the EMERALD trial, 43% were 65 years of age or older and 17% were 75 years of age or older. No overall differences in safety or effectiveness of ORSERDU were observed between patients 65 years or older of age compared to younger patients. There are an insufficient number of patients 75 years of age or older to assess whether there are differences in safety or effectiveness.","Paediatric use":"The safety and effectiveness of ORSERDU in pediatric patients have not been established.","Hepatic impairment":"Avoid use in patients with severe hepatic impairment (Child-Pugh C). Reduce the dosage for patients with moderate hepatic impairment (Child-Pugh B)."}},"trials":[],"aliases":[],"company":"Stemline Therap","patents":[{"applNo":"N217639","source":"FDA Orange Book","status":"Active","expires":"Feb 28, 2037","useCode":"U-3523","territory":"US","drugProduct":false,"patentNumber":"11819480","drugSubstance":false},{"applNo":"N217639","source":"FDA Orange Book","status":"Active","expires":"Oct 3, 2036","useCode":"U-3524","territory":"US","drugProduct":false,"patentNumber":"10420734","drugSubstance":false},{"applNo":"N217639","source":"FDA Orange Book","status":"Active","expires":"Aug 18, 2026","useCode":"U-3523","territory":"US","drugProduct":true,"patentNumber":"7612114","drugSubstance":true},{"applNo":"N217639","source":"FDA Orange Book","status":"Active","expires":"Jan 5, 2038","useCode":"U-3523","territory":"US","drugProduct":false,"patentNumber":"10745343","drugSubstance":false},{"applNo":"N217639","source":"FDA Orange Book","status":"Active","expires":"Oct 10, 2034","useCode":"U-3524","territory":"US","drugProduct":false,"patentNumber":"10071066","drugSubstance":false},{"applNo":"N217639","source":"FDA Orange Book","status":"Active","expires":"Oct 10, 2034","useCode":"U-3524","territory":"US","drugProduct":false,"patentNumber":"11779552","drugSubstance":false},{"applNo":"N217639","source":"FDA Orange Book","status":"Active","expires":"Jan 5, 2038","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10385008","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ELACESTRANT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:43:25.978944+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:43:24.090563+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:43:31.663233+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:43:22.695723+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELACESTRANT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:43:32.029633+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:22.173040+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:22.173061+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:22.173065+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:43:33.622508+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Estrogen receptor alpha degrader","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:43:33.125349+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594273/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:43:32.737467+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA217639","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:43:22.173067+00:00"}},"allNames":"orserdu","offLabel":[],"synonyms":["elacestrant","elacestrant dihydrochloride","orserdu","RAD1901"],"timeline":[{"date":"2023-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from STEMLINE THERAPEUTICS INC to Stemline Therap"},{"date":"2026-08-18","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7612114 expires"},{"date":"2028-01-27","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"},{"date":"2038-01-05","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 10385008 expires"}],"aiSummary":"Orserdu (ELACESTRANT) is a small molecule estrogen receptor antagonist developed by STEMLINE THERAPEUTICS INC and currently owned by Stemline Therap. It targets the estrogen receptor and is approved for the treatment of ESR1-mutated advanced or metastatic breast cancer, estrogen receptor-positive advanced or metastatic breast cancer, and HER2-negative advanced or metastatic breast cancer. Orserdu was FDA-approved in 2023 and has a half-life of 30 to 50 hours. The commercial status of Orserdu is patented, with no generic manufacturers available. Key safety considerations include its mechanism of action as an estrogen receptor antagonist.","approvals":[{"date":"2023-01-27","orphan":false,"company":"STEMLINE THERAPEUTICS INC","regulator":"FDA"}],"brandName":"Orserdu","ecosystem":[{"indication":"ESR1-mutated advanced or metastatic breast cancer","otherDrugs":[],"globalPrevalence":null},{"indication":"Estrogen receptor positive advanced or metastatic breast cancer","otherDrugs":[],"globalPrevalence":null},{"indication":"HER2-negative advanced or metastatic breast cancer","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Estrogen receptor","novelty":"Follow-on","targets":[{"gene":"ESR1","source":"DrugCentral","target":"Estrogen receptor","protein":"Estrogen receptor"},{"gene":"ESR2","source":"DrugCentral","target":"Estrogen receptor beta","protein":"Estrogen receptor beta"}],"moaClass":"Breast Cancer Resistance Protein Inhibitors","modality":"Small Molecule","drugClass":"Estrogen Receptor Antagonist [EPC]","explanation":"Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ER). In ER-positive (ER+) HER2-negative (HER2-) breast cancer cells, elacestrant inhibited 17-estradiol mediated cell proliferation at concentrations inducing degradation of ER protein mediated through proteasomal pathway. Elacestrant demonstrated in vitro and in vivo antitumor activity including in ER+ HER2- breast cancer models resistant to fulvestrant and cyclin-dependent kinase 4/6 inhibitors and those harboring estrogen receptor gene (ESR1) mutations.","oneSentence":"Orserdu works by blocking the estrogen receptor, a protein that helps cancer cells grow.","technicalDetail":"Orserdu (ELACESTRANT) is a selective estrogen receptor antagonist that binds to the estrogen receptor, preventing the binding of estrogen and thereby inhibiting the transcription of estrogen-responsive genes."},"commercial":{"launchDate":"2023","_launchSource":"DrugCentral (FDA 2023-01-27, STEMLINE THERAPEUTICS INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5710","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ELACESTRANT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELACESTRANT","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:53:28.983574","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:43:36.498102+00:00","fieldsConflicting":16,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bazedoxifene","drugSlug":"bazedoxifene","fdaApproval":"2013-10-03","relationship":"same-target"},{"drugName":"chlorotrianisene","drugSlug":"chlorotrianisene","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"conjugated estrogens","drugSlug":"conjugated-estrogens","fdaApproval":"1942-05-08","relationship":"same-target"},{"drugName":"demeclocycline","drugSlug":"demeclocycline","fdaApproval":"1960-01-14","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"diethylstilbestrol","drugSlug":"diethylstilbestrol","fdaApproval":"1973-05-30","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"estetrol","drugSlug":"estetrol","fdaApproval":"2021-04-15","relationship":"same-target"},{"drugName":"estradiol","drugSlug":"estradiol","fdaApproval":"1975-07-23","patentExpiry":"Nov 21, 2032","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"estradiol cypionate","drugSlug":"estradiol-cypionate","fdaApproval":"1979-08-15","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"estramustine phosphate","drugSlug":"estramustine-phosphate","fdaApproval":"1981-12-24","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"estriol","drugSlug":"estriol","fdaApproval":"","relationship":"same-target"}],"exclusivity":[{"code":"NCE","date":"Jan 27, 2028"},{"code":"NCE","date":"Jan 27, 2028"}],"genericName":"elacestrant","indications":{"approved":[{"name":"ESR1-mutated advanced or metastatic breast cancer","source":"DrugCentral","snomedId":254837009,"regulator":"FDA","eligibility":"postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy"},{"name":"Estrogen receptor positive advanced or metastatic breast cancer","source":"DrugCentral","snomedId":254837009,"regulator":"FDA","eligibility":"postmenopausal women or adult men with ER-positive, HER2-negative breast cancer"},{"name":"HER2-negative advanced or metastatic breast cancer","source":"DrugCentral","snomedId":254837009,"regulator":"FDA","eligibility":"postmenopausal women or adult men with ER-positive, HER2-negative breast cancer"}],"offLabel":[],"pipeline":[]},"currentOwner":"Stemline Therap","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"bazedoxifene","brandName":"bazedoxifene","genericName":"bazedoxifene","approvalYear":"2013","relationship":"same-target"},{"drugId":"chlorotrianisene","brandName":"chlorotrianisene","genericName":"chlorotrianisene","approvalYear":"","relationship":"same-target"},{"drugId":"conjugated-estrogens","brandName":"conjugated estrogens","genericName":"conjugated estrogens","approvalYear":"1942","relationship":"same-target"},{"drugId":"demeclocycline","brandName":"demeclocycline","genericName":"demeclocycline","approvalYear":"1960","relationship":"same-target"},{"drugId":"diethylstilbestrol","brandName":"diethylstilbestrol","genericName":"diethylstilbestrol","approvalYear":"1973","relationship":"same-target"},{"drugId":"estetrol","brandName":"estetrol","genericName":"estetrol","approvalYear":"2021","relationship":"same-target"},{"drugId":"estradiol","brandName":"estradiol","genericName":"estradiol","approvalYear":"1975","relationship":"same-target"},{"drugId":"estradiol-cypionate","brandName":"estradiol cypionate","genericName":"estradiol cypionate","approvalYear":"1979","relationship":"same-target"},{"drugId":"estramustine-phosphate","brandName":"estramustine phosphate","genericName":"estramustine phosphate","approvalYear":"1981","relationship":"same-target"},{"drugId":"estriol","brandName":"estriol","genericName":"estriol","approvalYear":"","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":["Breast Cancer"],"enrollment":4220,"completionDate":"2032-10"},{"nctId":"NCT06923527","phase":"PHASE2","title":"Circulating Tumor DNA","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-09-30","conditions":["ER+ Breast Cancer"],"enrollment":50,"completionDate":"2027-09"},{"nctId":"NCT05963997","phase":"PHASE1,PHASE2","title":"A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Carrick Therapeutics Limited","startDate":"2023-10-09","conditions":["Metastatic Breast Cancer","Locally Advanced Breast Cancer","Breast Cancer"],"enrollment":49,"completionDate":"2026-03-06"},{"nctId":"NCT05573126","phase":"PHASE1,PHASE2","title":"Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","status":"RECRUITING","sponsor":"Ellipses Pharma","startDate":"2023-01-11","conditions":["Hormone Receptor-positive Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":95,"completionDate":"2028-02"},{"nctId":"NCT07209449","phase":"PHASE2","title":"A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-01","conditions":["Endometrial Cancer"],"enrollment":75,"completionDate":"2028-10-01"},{"nctId":"NCT06120283","phase":"PHASE1","title":"BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2023-12-01","conditions":["Advanced Solid Tumor","Advanced Breast Cancer","Metastatic Breast Cancer","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive Breast Carcinoma","Hormone Receptor Positive Malignant Neoplasm of Breast","HER2-negative Breast Cancer","Hormone Receptor Positive HER-2 Negative Breast Cancer","Non-small Cell Lung Cancer"],"enrollment":300,"completionDate":"2028-06"},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":["Ductal Carcinoma in Situ"],"enrollment":400,"completionDate":"2033-11"},{"nctId":"NCT06382948","phase":"PHASE3","title":"Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.","status":"RECRUITING","sponsor":"MedSIR","startDate":"2024-12-05","conditions":["Advanced Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","ESR1 Gene Mutation"],"enrollment":240,"completionDate":"2028-04"},{"nctId":"NCT07467772","phase":"PHASE2","title":"Ph 2 Elacestrant in ER Positive Uterine Sarcomas","status":"NOT_YET_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2026-02","conditions":["Uterine Sarcoma","Uterine Leiomyosarcoma","Endometrial Stromal Sarcoma","ESS","Perivascular Epithelioid Cell Tumors","Uterine Adenosarcoma","Uterine PEComa","Estrogen Receptor Positive Tumor","uLMS"],"enrollment":30,"completionDate":"2028-04"},{"nctId":"NCT06638307","phase":"PHASE1","title":"A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-10-25","conditions":["Advanced Breast Cancer"],"enrollment":240,"completionDate":"2026-10"},{"nctId":"NCT07395336","phase":"PHASE2","title":"Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)","status":"NOT_YET_RECRUITING","sponsor":"European Institute of Oncology","startDate":"2026-04","conditions":["Breast Cancer"],"enrollment":26,"completionDate":"2028-12"},{"nctId":"NCT05386108","phase":"PHASE1,PHASE2","title":"Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2022-08-31","conditions":["Breast Neoplasms","Brain Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","Central Nervous System Neoplasms","Brain Diseases","Central Nervous System Diseases"],"enrollment":73,"completionDate":"2026-12"},{"nctId":"NCT07222215","phase":"PHASE2","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","status":"RECRUITING","sponsor":"Kristina A. Fanucci","startDate":"2026-01-16","conditions":["Estrogen-receptor-positive Breast Cancer","Metastatic Breast Cancer","Breast Cancer","Hormone Receptor Positive Breast Cancer","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","HER2- Breast Cancer","ESR1 Gene Mutation","ER Wildtype","Breast Neoplasms"],"enrollment":297,"completionDate":"2030-10-01"},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":["Breast Cancer","ER-positive Breast Cancer","HER2-negative Breast Cancer","Metastatic Breast Cancer"],"enrollment":24,"completionDate":"2029-07-31"},{"nctId":"NCT05563220","phase":"PHASE1,PHASE2","title":"Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2023-01-24","conditions":["Breast Cancer","Metastatic Breast Cancer"],"enrollment":435,"completionDate":"2028-12-28"},{"nctId":"NCT06691035","phase":"PHASE1","title":"Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-11-04","conditions":["Breast Cancer Metastatic Breast Cancer","HER2-negative Breast Cancer"],"enrollment":18,"completionDate":"2027-11"},{"nctId":"NCT06201234","phase":"PHASE2","title":"Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2024-12-13","conditions":["Hormone Receptor Positive HER-2 Negative Breast Cancer","Advanced or Metastatic Breast Cancer","BRCA1 Mutation","BRCA2 Mutation"],"enrollment":176,"completionDate":"2028-12-31"},{"nctId":"NCT07159451","phase":"PHASE2","title":"A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-10-06","conditions":["Breast Cancer"],"enrollment":140,"completionDate":"2027-05-29"},{"nctId":"NCT07242352","phase":"PHASE3","title":"Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC","status":"NOT_YET_RECRUITING","sponsor":"West German Study Group","startDate":"2026-01-31","conditions":["Breast Cancer","HR+/HER2- Breast Cancer"],"enrollment":1520,"completionDate":"2033-09-30"},{"nctId":"NCT07198724","phase":"PHASE1,PHASE2","title":"ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sarah Sammons, MD","startDate":"2026-03","conditions":["Metastatic Breast Cancer","HER2 Low Breast Carcinoma","HER2-negative Breast Cancer","Breast Cancer","Breast Cancer Female"],"enrollment":65,"completionDate":"2038-06-01"},{"nctId":"NCT06062498","phase":"PHASE2","title":"Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-09-29","conditions":["Estrogen-receptor-positive Breast Cancer","HER2/Neu-Negative Breast Cancer","Advanced Breast Cancerv","Metastatic Breast Cancer"],"enrollment":174,"completionDate":"2027-07-01"},{"nctId":"NCT03778931","phase":"PHASE3","title":"Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","isPivotal":true,"startDate":"2019-05-10","conditions":["Breast Cancer"],"enrollment":478,"completionDate":"2024-08-22"},{"nctId":"NCT05512364","phase":"PHASE3","title":"Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2023-12-15","conditions":["ER-positive Breast Cancer","HER2-negative Breast Cancer","Stage IIB Breast Cancer","Stage III Breast Cancer"],"enrollment":220,"completionDate":"2035-11-01"},{"nctId":"NCT05596409","phase":"PHASE2","title":"ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2023-05-19","conditions":["Metastatic Breast Cancer"],"enrollment":61,"completionDate":"2027-07"},{"nctId":"NCT07005882","phase":"PHASE2","title":"Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2025-09-01","conditions":["Breast Cancer Patients","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","HR+/HER2- Breast Cancer","Radiation Therapy"],"enrollment":21,"completionDate":"2028-03-01"},{"nctId":"NCT05982093","phase":"PHASE2","title":"Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2023-02-03","conditions":["Breast Cancer","HER2-negative Breast Cancer","Hormone Receptor Positive Tumor","Premenopausal Breast Cancer"],"enrollment":48,"completionDate":"2026-02"},{"nctId":"NCT05618613","phase":"PHASE1,PHASE2","title":"Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Context Therapeutics Inc.","startDate":"2022-12-02","conditions":["Breast Cancer"],"enrollment":4,"completionDate":"2023-06-23"},{"nctId":"NCT06938711","phase":"PHASE1,PHASE2","title":"A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Context Therapeutics Inc.","startDate":"2023-06","conditions":["Breast Cancer"],"enrollment":0,"completionDate":"2023-12"},{"nctId":"NCT06126575","phase":"PHASE1","title":"A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2023-03-13","conditions":["Hepatic Impairment"],"enrollment":16,"completionDate":"2024-11-11"},{"nctId":"NCT06544577","phase":"","title":"Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC","status":"RECRUITING","sponsor":"SciClone Pharmaceuticals","startDate":"2024-07-13","conditions":["ESR1 Gene Mutation","Advanced Breast Cancer","Safety"],"enrollment":350,"completionDate":"2026-08-01"},{"nctId":"NCT04791384","phase":"PHASE1,PHASE2","title":"Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer","status":"UNKNOWN","sponsor":"Criterium, Inc.","startDate":"2022-04-21","conditions":["Breast Cancer"],"enrollment":44,"completionDate":"2025-01"},{"nctId":"NCT04797728","phase":"EARLY_PHASE1","title":"Elacestrant in Preoperative Setting, a Window of Opportunity Study","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2021-02-09","conditions":["Breast Cancer","Hormone Receptor Positive Breast Carcinoma"],"enrollment":23,"completionDate":"2022-02-25"},{"nctId":"NCT02650817","phase":"PHASE1","title":"Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2016-04-01","conditions":["Metastatic Breast Cancer"],"enrollment":16,"completionDate":"2019-10-18"},{"nctId":"NCT02338349","phase":"PHASE1","title":"A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Stemline Therapeutics, Inc.","startDate":"2015-01","conditions":["Advanced ER+, HER2-Negative Breast Cancer"],"enrollment":57,"completionDate":"2020-04"},{"nctId":"NCT02653417","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms","status":"TERMINATED","sponsor":"Radius Pharmaceuticals, Inc.","startDate":"2015-12","conditions":["Vasomotor Symptoms","Hot Flashes"],"enrollment":139,"completionDate":"2018-05-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT03778931"],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"ORSERDU"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"364875","NDDF":"019283","UNII":"FM6A2627A8","VANDF":"4042013","INN_ID":"10247","RXNORM":"2628469","UMLSCUI":"C4682404","chemblId":"CHEMBL4594273","ChEMBL_ID":"CHEMBL4297509","KEGG_DRUG":"D11671","DRUGBANK_ID":"DB06374","PDB_CHEM_ID":"I0V","PUBCHEM_CID":"23642301","IUPHAR_LIGAND_ID":"12339","MESH_SUPPLEMENTAL_RECORD_UI":"C000626176"},"formularyStatus":[],"originalProduct":{"form":"TABLET, FILM COATED","route":"ORAL","company":"Stemline Therapeutics, Inc.","brandName":"ORSERDU","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2023-","companyName":"Stemline Therapeutics Inc","relationship":"Original Developer"},{"period":"present","companyName":"Stemline Therap","relationship":"Current Owner"}],"pharmacokinetics":{"source":"FDA label","halfLife":"30 to 50 hours"},"publicationCount":107,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"originalDeveloper":"Stemline Therapeutics Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Stemline Therap","companyId":"stemline-therap","modality":"Small molecule","firstApprovalDate":"2023","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2023-01-27T00:00:00.000Z","mah":"STEMLINE THERAPEUTICS INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-01-27T00:00:00.000Z","mah":"STEMLINE THERAP","brand_name_local":null,"application_number":"NDA217639"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2023-01-27T00:00:00.000Z","mah":"STEMLINE THERAPEUTICS INC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2023-01-27T00:00:00.000Z","mah":"STEMLINE THERAPEUTICS INC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2023-01-27T00:00:00.000Z","mah":"STEMLINE THERAPEUTICS INC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2023-01-27T00:00:00.000Z","mah":"STEMLINE THERAPEUTICS INC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-01-27T00:00:00.000Z","mah":"STEMLINE THERAPEUTICS INC","brand_name_local":null,"application_number":""},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":"EMEA/H/C/005898"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Orserdu","application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:43:36.498102+00:00","fieldsConflicting":16,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}